OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic
treatment of the dry form of age-related macular degeneration. This pilot study of up to 10
eye drop tolerant participants with bilateral geographic atrophy is designed to characterize
the effect of 0.45% concentration of OT-551 eye drops given 3 times a day on the progression
of geographic atrophy area over a two-year period. Participants will have one eye randomized
to receive the eye drop and the fellow eye will be observed only.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC) Othera Pharmaceuticals
Collaborators:
National Eye Institute (NEI) Othera Pharmaceuticals